Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Reason given: Could not accrue
Key facts
- Where
- Miami, United StatesSee the site
- Phase
- Phase 1/2
Where in United States
- Miami Cancer Institute at Baptist Health of South FloridaMiami, United StatesNo longer taking part
Trial details
- Who runs it
- Guenther Koehne
- Trial code
- NCT04982354
- Record updated
- 1 October 2024
- Original description
This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.Read full original descriptionShow less
A Pilot Study of Daunorubicin-cytarabine Liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) as Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia Followed by Consolidation With a CD34+-Selected Allograft
This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.
Inclusion: Patients must have a Karnofsky (adult) Performance Status of at least 70%; Patients must have adequate organ function.
Exclusion: Active viral, bacterial or fungal infection; Patient seropositive for Human Immunodeficiency Virus (HIV-I /II); Human T-Cell Lymphotrophic Virus (HTLV -I /II); Female patients who are pregnant or breast-feeding; Presence of leukemia in the Central Nervous System (CNS).